GUMDROP : WHC - Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Created by Nancy Dawson, last modified on Sep 16, 2013
Description:This phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with metastatic kidney cancer who have no evidence of disease after surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
Link:http://www.clinicaltrials.gov/ct2/show/NCT01575548
Site:Washington Hospital Center
Principle Investigator:Dr. George Philips, MD